Collaboration and License Agreement - Additional Information (Detail) - USD ($)		12 Months Ended
	Nov. 06, 2020	Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license agreement date		Nov. 06, 2020
Collaborative arrangement, rights and obligations	The Company will also be entitled to receive tiered royalties ranging from low double digits to mid-teens on sales in the Territory, if any, of products containing AVB-500. Royalties are payable with respect to each jurisdiction in the Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Territory; or (iii) ten (10) years after the first commercial sale of a product in such jurisdiction in the Territory. In addition, royalties payable under the Agreement will be subject to reduction on account of generic competition under certain specified conditions, with any such reductions capped at certain percentages of the amounts otherwise payable during the applicable royalty payment period.
Transaction Price	$ 12,000,000
Research and development services performance obligation	6,400,000
Intellectual property obligation	5,600,000
Assessed clinical or regulatory milestones		$ 0
3D Medicines [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		5,600,000
Revenue from research and development services		100,000
Contract Liability		6,300,000
Contract Liability, current		2,600
Contract Liability, long-term		$ 3,700
Service period for future research and development services expected to occur		2 years 6 months
3D Medicines [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative agreement milestone cash payment	12,000,000
Proceeds from Collaborators		$ 12,000,000
3D Medicines [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Clinical development, regulatory and commercial milestone payments	$ 207,000,000
Stanford University [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative agreement milestone cash payment due		$ 132,000